Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
42.40    -1.40 (-3.20%)
Bid:
41.40
Ask:
43.40
Spread: 2.00 (4.831%)
Market Cap: £66.18m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Issue of Equity

2 Jun 2023 09:41

RNS Number : 5005B
Maven Income and Growth VCT 3 PLC
02 June 2023
 

Maven Income and Growth VCT 3 PLC (the Company)

 

Issue of Equity

 

On 7 October 2022, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £5 million, with an over-allotment facility for up to a further £5 million (the Offer).

 

Pursuant to the Offer, £819,220 of valid applications were received in the period from 7 October 2022 up to 12 noon on 26 May 2023 in respect of the 2023/2024 tax year. This is the first and final allotment in respect of the 2023/2024 tax year and, as a result, the Company has issued and allotted 1,441,593 new Ordinary Shares on 2 June 2023. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which these shares were issued were in the range of 56.27p to 57.18p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 115,358,633. Therefore, the total number of voting rights in the Company is 115,358,633.

 

The total funds raised by the Company for the 2022/2023 and the 2023/2024 tax years is £6,752,600.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares so issued to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence on or around 6 June 2023.

 

The above statement of Voting Capital may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

2 June 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFIFVTRAIFIIV
Date   Source Headline
27th Mar 20251:11 pmRNSDirector/PDMR Shareholding
27th Mar 20251:06 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:53 pmRNSUnaudited Net Asset Value
18th Mar 20253:37 pmRNSAnnual Financial Report
28th Feb 20254:32 pmRNSTransaction in Own Shares
27th Feb 20251:54 pmRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:17 amRNSDirector/PDMR Shareholding
19th Feb 202510:14 amRNSDirector/PDMR Shareholding
19th Feb 202510:06 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
18th Dec 20249:35 amRNSIssue of Equity
13th Dec 20242:42 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
25th Oct 20243:49 pmRNSTransaction in Own Shares
27th Sep 20244:31 pmRNSPublication of a Prospectus
6th Sep 202410:25 amRNSDirector/PDMR Shareholding
6th Sep 202410:01 amRNSIssue of Equity
5th Sep 20242:26 pmRNSStatement re Dividend Investment Scheme
5th Sep 20241:40 pmRNSUnaudited Net Asset Value
18th Jul 20245:27 pmRNSHalf-year Report
10th Jul 20245:08 pmRNSTransaction in Own Shares
8th Jul 20244:07 pmRNSStatement re NAV and Interim Dividend
18th Jun 202411:53 amRNSStatement re Intended Offers for Subscription
10th May 20244:11 pmRNSTransaction in Own Shares
3rd May 20249:35 amRNSDirector/PDMR Shareholding
3rd May 20249:33 amRNSIssue of Equity
2nd May 20241:31 pmRNSResult of AGM
1st May 202410:06 amRNSDirector/PDMR Shareholding
1st May 202410:03 amRNSIssue of Equity
26th Apr 20242:40 pmRNSNet Asset Value - Dividend Investment Scheme
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:37 pmRNSIssue of Equity
28th Mar 202410:16 amRNSStatement re Offer for Subscription
27th Mar 202410:36 amRNSIssue of Equity
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:46 pmRNSUnaudited Net Asset Value
15th Mar 20245:18 pmRNSAnnual Financial Report
21st Feb 20244:24 pmRNSTransaction in Own Shares
8th Feb 202410:30 amRNSDirector/PDMR Shareholding
8th Feb 202410:28 amRNSDirector/PDMR Shareholding
8th Feb 202410:15 amRNSIssue of Equity
6th Feb 202411:07 amRNSDividend Declaration
19th Dec 20233:25 pmRNSIssue of Equity
18th Dec 20235:17 pmRNSUnaudited Net Asset Value
5th Dec 202311:42 amRNSDirectorate Change
9th Nov 20233:47 pmRNSResult of General Meeting
8th Nov 20234:01 pmRNSTransaction in Own Shares
7th Nov 20234:47 pmRNSTransaction in Own Shares
19th Oct 20234:15 pmRNSNet Asset Value

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.